Tanox Biosystems Inc. announced that it has regained therights to its anti-HIV monoclonal antibody project from itsdevelopment partner, Ciba-Geigy Ltd.
Ciba-Geigy's decision is apparently part of an internal review ofits research projects. The decision "results, in part, from theuncertainty of successful clinical development of Tanox's anti-HIV neutralizing antibodies based on current assaytechnology," according to the company.
This decision will not affect the collaboration between the twocompanies on developing monoclonal antibody-based productsfor treating allergies and allergic asthma.
Meanwhile, one of Tanox's anti-HIV neutralizing monoclonalantibodies, AIDS-439, will be tested in an upcoming clinicaltrial. The Houston company said that the National Institutes ofHealth's (NIH) AIDS Clinical Drug Development Committee hasrecommended that Phase I trials of AIDS-439 be carried out ina perinatal setting in collaboration with the AIDS Clinical TrialsGroup.
(c) 1997 American Health Consultants. All rights reserved.